Ferric Carboxymaltose: A Review in Iron Deficiency
- 461 Downloads
Intravenous ferric carboxymaltose (Ferinject®; Injectafer®) is a colloidal solution of nanoparticles which consist of a polynuclear iron (III)-(oxyhydr)oxide core stabilized by carboxymaltose and may be given as a single high-dose, 15-min infusion. This article reviews the clinical use of ferric carboxymaltose in various patient populations with iron deficiency (ID) [± anaemia] and briefly summarizes its pharmacological properties. Based on extensive experience in the clinical trial and real-world settings, ferric carboxymaltose is an effective and generally well tolerated treatment for rapidly replenishing iron stores and correcting anaemia in patients with ID (± anaemia) of various aetiologies, including patients with chronic heart failure (CHF), chronic kidney disease, inflammatory bowel disease or perioperative anaemia, and women with ID during pregnancy, postpartum or associated with heavy uterine bleeding. As it may be given as a single high-dose infusion, ferric carboxymaltose has the potential to provide cost savings from a healthpayer perspective. Thus, ferric carboxymaltose remains an important option for the treatment of ID in adults and, where approved, children aged ≥ 14 years, when oral iron preparations are ineffective or cannot be used.
During the peer review process, the manufacturer of ferric carboxymaltose was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/312DF06004B89E77.
- 6.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2016;18:891–975.CrossRefPubMedGoogle Scholar
- 9.American Regent Inc. Injectafer® (ferric carboxymaltose injection): US prescribing information. 2013. http://www.fda.gov. Accessed 6 Feb 2018.
- 10.Vifor Pharma UK Limited. Ferinject (ferric carboxymaltose): UK summary of product characteristics. 2017. http://www.medicines.org.uk. Accessed 9 Feb 2018.
- 18.Charytan C, Bernardo MV, Koch TA, et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant. 2013;28(4):953–64.CrossRefPubMedGoogle Scholar
- 21.Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599–607.CrossRefPubMedGoogle Scholar
- 22.Macdougall IC, Bock AH, Carrera F, et al. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. BMC Nephrol. 2017;18(24):1–18.Google Scholar
- 23.Benjamin J, Qunibi WY. Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non-dialysis dependent-CKD patients with or without ESA therapies [abstract no. SA-PO2422]. J Am Soc Nephrol. 2009;20(Suppl):666A.Google Scholar
- 26.Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846–53.e1-2.Google Scholar
- 29.Stein J, Vollmer S, Klemm W, et al. Safety and efficacy of Ferinject® in the treatment of IBD-related iron deficiency anaemia under daily practice conditions: results from a non-interventional post-marketing surveillance study in Germany [abstract no. P0881]. United Eur Gastroenterol J. 2016;3(5 Suppl.):A456–7.Google Scholar
- 53.Schatz U, Illigens BM, Siepmann T, et al. TIDILAP: treatment of iron deficiency in lipoprotein apheresis patients. A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Atheroscler Suppl. 2015;18:199–208.CrossRefPubMedGoogle Scholar
- 56.Robalo Nunes A, Palricas Costa A, Rocha SL, et al. Efficacy and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency at a hospital outpatient clinic: a retrospective cohort study of real-world clinical practice. Anemia. 2017. https://doi.org/10.1155/2017/3106890.PubMedPubMedCentralGoogle Scholar
- 57.Bach M, Geisel T, Martin J, et al. Efficacy and safety of intravenous ferric carboxymaltose in geriatric inpatients at a German tertiary university teaching hospital: a retrospective observational cohort study of clinical practice. Anemia. 2015. https://doi.org/10.1155/2015/647930.PubMedPubMedCentralGoogle Scholar
- 67.Cappellini MD, Comin-Colet J, Francisco A, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hepatol. 2017;92(10):1068–78.Google Scholar
- 68.Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017;23(8):628–51.CrossRefPubMedGoogle Scholar
- 72.Jimenez K, Kulnigg-Dabsch S, Gasche C. Management of iron deficiency anemia. Gastroenterol Hepatol. 2015;11(4):241–50.Google Scholar
- 78.Favreau A, Langseder A, Neier M, et al. Safety and efficacy of ferric carboxymaltose in pediatric inflammatory bowel disease [abstract no. PD-198]. Inflamm Bowel Dis. 2017;23(Suppl. 1):S66.Google Scholar
- 83.Froessler B, Foerster D, Hardt T, et al. Treatment cost effects of perioperative anaemia treatment with ferric carboxymaltose [abstract no. P86]. Transfus Med. 2017;27(Suppl. 1):57.Google Scholar